Clinical Trials for Selumetinib

2 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCTHN1379
02/21/2014
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB/IV) (SELECT-1)
TreatmentVICCTHN1318
09/19/2013
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.